PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Arjun Balar, MD - Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy
Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.